Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer.
Catherine Handy MarshallLukasz P GondekViolet DanielsChangxue LuSergiu PascaJiajun XieMark C MarkowskiChanning J PallerLaura A SenaSamuel R DenmeadeJun LuoEmmanuel S AntonarakisPublished in: The Prostate (2024)
CH alterations are frequently found after treatment with PARP inhibitors in patients with prostate cancer and this may be one mechanism by which PARP inhibitors lead to increased risk of MDS/AML.